Last updated on August 2019

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk


Brief description of study

Primary Objectives:

To demonstrate that, when compared to placebo in patients with type 2 diabetes (T2D), cardiovascular (CV) risk factors, and moderately impaired renal function, sotagliflozin:

  • Does not increase the risk of cardiovascular events including death from cardiovascular disease, non-fatal heart attack and non-fatal stroke;
  • Reduces the risk of death from CV disease or hospitalization for heart failure.

Secondary Objectives:

  • To demonstrate that, when compared to placebo in patients with T2D, CV risk factors, and moderately impaired renal function, sotagliflozin:
  • Reduces cardiovascular events including death from cardiovascular disease, non-fatal heart attack and non-fatal stroke;
  • Reduces risk of progression of kidney disease;
  • Reduces cardiovascular events including death from cardiovascular disease and emergency treatment for heart failure;
  • Reduces death from cardiovascular disease;
  • Reduces death from any cause.
  • To assess the safety and tolerability of sotagliflozin.

Detailed Study Description

Study duration per participant is approximately 27 to 51 months, assuming approximately 24 months of recruitment, and approximately 27 months of follow-up after the last patient is randomized.

Clinical Study Identifier: NCT03315143

Find a site near you

Start Over

Investigational Site Number 8400039

Beverly Hills, CA United States
  Connect »

Investigational Site Number 8400006

Huntington Park, CA United States
  Connect »

Investigational Site Number 8400088

North Miami Beach, FL United States
  Connect »

Investigational Site Number 8400026

Pembroke Pines, FL United States
  Connect »

Investigational Site Number 8400058

Saint Petersburg, FL United States
  Connect »

Investigational Site Number 8400085

Arlington Heights, IL United States
  Connect »

Investigational Site Number 8400125

Michigan City, IN United States
  Connect »

Investigational Site Number 8400020

Morehead City, NC United States
  Connect »

Investigational Site Number 8400048

Morehead City, NC United States
  Connect »

Investigational Site Number 8400067

Corpus Christi, TX United States
  Connect »

Investigational Site Number 8400060

South Burlington, VT United States
  Connect »

Investigational Site Number 0320014

Ciudad Autonoma De Bs.As, Argentina
  Connect »

Investigational Site Number 0320023

Ciudad Autonoma De Buenos Aire, Argentina
  Connect »

Investigational Site Number 0320021

San Miguel De Tucuman, Argentina
  Connect »